Antisense modulation of glioma-associated oncogene-2 expression
AssigneeIsis Pharmaceuticals, Inc.
InventorsC. Frank Bennett, Susan M. Freier
Life of this patent
Estimating the term…
Abstract
Antisense compounds, compositions and methods are provided for modulating the expression of glioma-associated oncogene-2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding glioma-associated oncogene-2. Methods of using these compounds for modulation of glioma-associated oncogene-2 expression and for treatment of diseases associated with expression of glioma-associated oncogene-2 are provided.
Claims26
A compound 8 to 50 nucleobases in length targeted to nucleobases 142 through 490 of a 5′-untranslated region, nucleobases 607 through 4346 of a coding region, or nucleobases 4379 through 4849 of a 3′-untranslated region of a nucleic acid molecule encoding human glioma-associated oncogene-2 of SEQ ID NO:
- 3, wherein said compound specifically hybridizes with said nucleic acid molecule encoding human glioma-associated oncogene-2 and inhibits the expression of human glioma-associated oncogene-2.
A compound up to 50 nucleobases in length comprising at least an 8-nucleobase portion of SEQ ID NO:
- 10, 13, 18, 24, 27, 29, 30, 31, 34, 35, 36, 40, 41, 45, 47, 50, 52, 55, 56, 58, 59, 64, 65, 70, 74 or 82 which inhibits the expression of human glioma-associated oncogene-2.
Dependencies are inferred from the claim text.